Appendix Table C18. KQ1 Outcome II. Transfusion: Darbepoetin versus epoetin

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study ID** | **Darbepoetin (n)** | **Darbepoetin (N)** | **Percentage (%)** | **Epoetin (n)** | **Epoetin (N)** | **Percentage (%)** | **Wks included** | **Comments** |
| **Baseline Hb below < 10g/dL** |  |  |  |  |  |  |  |  |
| Glaspy 2002 Part A, c (1.5 µg/kg/qw) | 9 | 35 | 25.71% | 12 | 53 | 22.64% | 5-13 | K-M percentages reported, c: 26% 95% CI (9; 43), EPO 23% 95% CI (10; 36) |
| **Glaspy 2002 Part A, d\* (2.25 µg/kg/qw)** | **8** | **59** | **13.56%** | **see above** | **see above** | **see above** | **see above** | **d: 13% 95% CI** **(4; 23)** |
| Glaspy 2002 Part A, e (4.5 µg/kg/qw) | 2 | 29 | 6.90% | see above | see above | see above | see above | e: 6% 95% CI (2; 30) |
|  |  |  |  |  |  |  |  |  |
| **Baseline Hb below 10-12 g/dL** |  |  |  |  |  |  |  |  |
| Schwartzberg 2004 a (breast cancer) | 4 | 72 | 5.56% | 11 | 69 | 15.94% | 1-16 | percentages reported (a: 6% vs 16%, b: 27% vs 18%, c: 21% vs 17%) |
| Schwartzberg 2004 b (lung cancer) | 14 | 51 | 27.45% | 9 | 51 | 17.65% |  |  |
| Schwartzberg 2004 c (gynecological) | 7 | 34 | 20.59% | 6 | 35 | 17.14% |  |  |
| Glaspy 2006  | 157 | 582 | 26.98% | 126 | 571 | 22.07% | 1- 17 | K-M percentages reported, darb: 27%, EPO 22% |
| Waltzman 2005 | 29 | 163 | 17.79% | 20 | 155 | 12.90% | 5 to end of treatment period (wk 17)  | p=0.2936 logistic regression, adjusted for CT |
| Kotsori 2006 | 9 | 55 | 16.4% | 3 | 55 | 5.5% | NR | assumed 1:1 randomization |

\*Glaspy 2002 A d is the arm used as main results for the meta-analysis. The arms c and e were applied for sensitivity analysis.